Day: February 8, 2022

New Division Brings Together the Legacy Tilray and Aphria Medical Businesses; Includes Expanded Offerings in Canada TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the launch of Tilray Medical, a global medical platform that unifies the Company’s medical cannabis brands under one strategy, mission, and vision.  Denise Faltischek, Head of International and Chief Strategy Officer, said, “Tilray is the global leader in the advancement of cannabinoid-based medicine, with a focus on providing research-backed medical cannabis products to physicians, pharmacies, and patients....

SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022. Details on the presentation include: SVB Leerink 11th Annual Global Healthcare ConferencePresentation Date: Thursday, February 17th, 2022Time: 11:20 a.m. ET A webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days. About AdageneAdagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company...

CHICAGO and PITTSBURGH, Feb. 08, 2022 (GLOBE NEWSWIRE) — FARMACEUTICALRX, one of the largest producers of premium organic medical marijuana products in the US market, (“FARMACEUTICALRX” or the “Company”), today announced that it has closed a $34 million senior secured term loan (the “Senior Term Loan”) provided by Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic”), a commercial real estate finance company, and other institutional lenders. The Senior Term Loan proceeds will be used to complete the funding of the Company’s Ohio Level 1 cultivation and post-harvest facility, repay existing debt, fund equipment purchases, and for general working capital purposes. The Company brings its cultivation and processing methods from the FARMACEUTICALRX of Pennsylvania operations to the 100,000 square...

Figure 1Troilus Property and Regional Exploration TargetsFigure 2Testard Target; 2021 Drilling ProgramTORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Troilus Gold Corp. (“Troilus” or the “Company”, TSX: TLG; OTCQX: CHXMF) provides an overview of the extensive regional exploration activities completed in the second half of 2021 at its Troilus gold-copper project located in northcentral Quebec, Canada. Exploration work focused on several prospective targets inherited from the acquisition of UrbanGold Minerals earlier in the year (see March 23, 2021, press release) (See Figure 1). The Company also reports the completion of a ~1,200 metre scout drilling program at Testard, a prospective target located approximately 10 kilometres south of the main mineral corridor and former mine site, where previously...

  Conference Call and Webcast    Today, February 8, 2022 at 10:00 a.m. ET    773-305-6853, conference ID 2580362 or www.bbgi.com         Replay information provided below  NAPLES, Fla., Feb. 08, 2022 (GLOBE NEWSWIRE) — Beasley Broadcast Group, Inc. (Nasdaq: BBGI) (“Beasley” or the “Company”), a multi-platform media company, today announced operating results for the for the three- and twelve-month periods ended December 31, 2021. Summary of Fourth Quarter and Full Year ResultsIn millions, except per share data Three Months EndedDecember 31, Twelve Months EndedDecember 31,    2021   2020   2021   2020Net revenue $70.7 $68.5 $241.4 $206.1Operating income (loss) 1   6.5   19.6   14.7   (4.3)Net income (loss) 1   10.6   11.0   (1.5)   (18.9)Net income (loss) per diluted share 1 $0.36 $0.38 ($0.05) ($0.63)Station...

AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patients At the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and children that received AGTC-401 were responders based on improvements in visual sensitivity Totality of data from adult and pediatric patients indicate biologic activity and reaffirm previous positive safety findings in adults Company to host conference call to review data today at 8:00 a.m. ETGAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus...

LOUDON, Tenn., Feb. 08, 2022 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) today announced its financial results for the second quarter ended December 31, 2021. Fiscal Second Quarter 2022 Highlights Compared to Fiscal Second Quarter 2021:Net sales increased 34.9% to a record $263.9 million Unit volume increased 19.0% to a record 2,073 units Gross profit increased 28.4% to a record $63.6 million Net income increased 39.9% to a record $31.0 million Adjusted EBITDA increased 23.0% to a record $48.1 million Net income available to Class A Common Stock per share (diluted) increased 39.6% to a record $1.41 per share Adjusted fully distributed net income per share increased 23.0% to a record $1.50 per share on a fully distributed weighted average share count of 21.7 million shares of Class A Common Stock“We delivered...

Figure 13D View of Kiena A ZoneFigure 2Kiena Basalt ZoneTORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO) (“Wesdome” or the “Company”) today announces underground exploration drilling results from the Kiena Deep A Zone at the Company’s 100% owned Kiena Mine Complex in Val d’Or, Quebec. Recent underground definition and exploration drilling at the Kiena Deep A Zones area has:Confirmed the A Zone continues down plunge along the basalt – ultramafic contact with drilling returning high grade from this continuous zone of mineralization (Figure 1); Confirmed the Footwall Zone comprises three subparallel zones and one crosscutting zone that have now been extended over 300 metres down plunge. Mineralization remains open laterally and down plunge and additional drilling...

Dr. Bo LonnerdalDr. Bo LonnerdalA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e522a2cf-385d-4ca9-8c98-266c71f43a8d VANCOUVER, British Columbia, Feb. 08, 2022 (GLOBE NEWSWIRE) —  ELSE NUTRITION HOLDINGS INC (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company, is pleased to announce that Dr. Bo Lönnerdal has joined its Scientific Advisory Board. Dr. Lönnerdal is the Distinguished Professor Emeritus of Nutrition & Internal Medicine at University of California, Davis (UCD). He has an active research program in pediatric nutrition at UCD. He has mentored many undergraduate and graduate students, as well as post-doctoral scholars and visiting scientists from across the world....

Expedited Clinical Program Reduces Capital Requirements KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced updates to its 2022 clinical program for its lead candidate CTx-1301, an investigational asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). This year, the Company plans to initiate its CTx-1301 Phase 3 clinical studies: a fixed-dose pediatric and adolescent safety and efficacy study, a dose-optimization study extension, and a pediatric safety and efficacy study to assess the onset and duration of efficacy. Specifically, the pivotal, fixed-dose...